Ascletis Announces First Participants with Obesity or Overweight Dosed in a U.S. 13-week Phase IIa Study of Small Molecule Oral

• click to rate

  Posted by Two Blokes Jul 3 - Filed in Stock - 4 views
  
  -  First p articipants with obesity or o verweight w ith at least one w eight- r elated c omorbidity have been d osed in a U.S. 13-week Phase IIa study of s mall m olecule o ral GLP-1  receptor a gonist ASC30. -  ASC30 oral once-daily tablet demonstrated up to 6.5% placebo-adjusted mean  body weight reduction from baseline after four-week treatment in a U.S. Phase Ib study.